Moderna
MRNA
$103.89
Share price
-4.56%
Change (1 day)
-24.79%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.
Moderna (MRNA) - P/B ratio
P/B ratio as of April 2024 : 3.01
According to Moderna
's latest financial reports the company has a price-to-book ratio of 3.01.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Moderna - P/B ratio (from 2018 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 2.74 | -24.15% |
| 2022-12-31 | 3.61 | -50.43% |
| 2021-12-31 | 7.28 | -54.9% |
| 2020-12-31 | 16.1 | 188.09% |
| 2019-12-31 | 5.60 | 70.78% |
| 2018-12-31 | 3.28 | |
| 2017-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.20 | 73.00% | 🇺🇸 USA |
 Novartis NVS | 4.30 | 43.02% | 🇨🇭 Switzerland |
 Merck MRK | 8.55 | 184.14% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | 5.14 | 70.96% | 🇺🇸 USA |
 Athersys ATHX | -0.0229 | -100.76% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -82.4 | -2,839.54% | 🇺🇸 USA |
 Arrowhead Pharmaceuticals
ARWR | 16.6 | 452.18% | 🇺🇸 USA |